27.02.2013 • News

CordenPharma Expands with ICIG Acquisition of Farchemia

CordenPharma announces an expansion of manufacturing capabilities due to the recent acquisition by International Chemical Investors Group (ICIG) of Farchemia from the Tessenderlo Group, completed on December 5th, 2012.

Farchemia, located in Bergamo, Italy, brings to CordenPharma expanded capabilities in developing and manufacturing advanced intermediates and APIs for the pharmaceutical industry in all major markets. Farchemia's portfolio is comprised of cGMP custom synthesis from lab to multi-ton scale, multi-step API process development, contract manufacturing, and full suite of proprietary generic APIs. Farchemia employs approximately 150 people and generates nearly €50 million in annual sales.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

Article

The State of the US Specialty Chemicals Industry
Reshaping Specialty Chemicals Manufacturing

The State of the US Specialty Chemicals Industry

SOCMA's Jenn Klein examines how specialty chemical manufacturers — the invisible backbone behind pharmaceuticals, electronics, agriculture, and energy — are navigating supply chain shifts, policy uncertainty, and constant change while remaining resilient, disciplined, and focused on execution.

Top-Feature

most read

Photo
News • Chemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.